Elan Osake

Elan P/FCF

P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Elan (6099.T) 13.8.2026 päivämäärällä on 14,15. Edellisenä vuonna P/FCF (Hinta-vapaa-kassavirta-suhde) oli 12,36 — muutos 14,49 % (korkeampi).

P/FCF

14,15

YoY

14,49%

Viimeksi päivitetty:

P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Elan on 2026 14,15 . P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Elan oli 2025 12,36 . Se laskee 14,49% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Elan Osakeanalyysi

Mitä Elan tekee? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Elan osakkeesta

Yhtiön Elan P/FCF (Hinta-vapaa-kassavirta-suhde) on 14,15 vuonna 2026.

P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Elan muuttui arvosta 12,36 arvoon 14,15, mikä edustaa 14,49 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää P/FCF (Hinta-vapaa-kassavirta-suhde) Elan:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Hinta-vapaa-kassavirta-suhde mittaa, kuinka paljon sijoittajat maksavat jokaista vapaan kassavirran yksikköä kohti. Matalampi suhde voi viitata parempaan arvoon.

P/FCF = Markkina-arvo / Vapaa kassavirta

Arvioidakseen P/FCF (Hinta-vapaa-kassavirta-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja P/FCF (Hinta-vapaa-kassavirta-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata P/FCF (Hinta-vapaa-kassavirta-suhde):n Elan alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Elan

Kaikki tunnusluvut — Elan